Reviva Pharmaceuticals Holdings (RVPH) Tax Provisions (2021 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted Tax Provisions of $3346.0 for Q1 2026, up 123.32% sequentially from -$14348.0 in Q4 2025, and down 35.81% YoY from $5213.0 in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) Tax Provisions (2021 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Tax Provisions for 6 years, with the latest figure at $3346.0 in Q1 2026.
- Quarterly Tax Provisions fell 35.81% year-over-year to $3346.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$208.0 (down 101.2% YoY) and the FY2025 annual result came in at $1659.0, down 91.5% from the prior year.
- Tax Provisions grew to $3346.0 in Q1 2026 per RVPH's latest filing, from -$14348.0 in the prior quarter.
- Over five years, Tax Provisions peaked at $12117.0 in Q3 2023 and troughed at -$113143.0 in Q4 2023.
- A 5-year average of -$3916.8 and a median of $4181.0 in 2022 frame the typical range for Tax Provisions.
- The widest YoY moves for Tax Provisions: up 550.05% in 2023, down 1316.06% in 2023.
- Over 5 years, Tax Provisions stood at -$7990.0 in 2022, then plunged by 1316.06% to -$113143.0 in 2023, then soared by 104.18% to $4733.0 in 2024, then sank by 403.15% to -$14348.0 in 2025, then jumped by 123.32% to $3346.0 in 2026.
- According to Business Quant data, Tax Provisions over the past three periods registered $3346.0, -$14348.0, and $2840.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Reviva Pharmaceuticals Holdings | 6.74 Mn | 6.74 Mn | - | 2,632.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2,632.00 |
| Mar 31, 2026 | 3,346.00 |
| Dec 31, 2025 | -14,348.00 |
| Sep 30, 2025 | 2,840.00 |
| Jun 30, 2025 | 7,954.00 |
| Mar 31, 2025 | 5,213.00 |
| Dec 31, 2024 | 4,733.00 |
| Jun 30, 2024 | 7,385.00 |
| Mar 31, 2024 | 7,396.00 |
| Dec 31, 2023 | -113,143.00 |
| Sep 30, 2023 | 12,117.00 |
| Jun 30, 2023 | 6,436.00 |
| Mar 31, 2023 | 2,978.00 |
| Dec 31, 2022 | -7,990.00 |
| Sep 30, 2022 | 1,864.00 |
| Jun 30, 2022 | 6,921.00 |
| Mar 31, 2022 | 3,629.00 |
| Sep 30, 2021 | 2,102.00 |
| Jun 30, 2021 | 3,902.00 |
| Mar 31, 2021 | 800.00 |